

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Naoyoshi Yamada

Application No.: 10/596,827

Confirmation No.: 1997

Filed: June 26, 2006

Art Unit: N/A

For: OCTAHYDRONAPHTHALENE
DERIVATIVE AND MEDICINE

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:
(Check one of the boxes A-D)

- ☐ A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above identified national application
- ☒ B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- ☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

☐ i. Counsel states that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b))

☐ (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

☐ ii. Payment in the amount of the fee set forth in 1.17(p), presently believed to be \$180, is indicated below.

☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 CFR 1.17(i) a check in the amount of \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was

(check one of the boxes "a" and "b" below:)

☐ (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate.)

- ☐ A. Pursuant to the 37 C.F.R. § 1.98(a)(2)(ii), a copy/copies of the U.S. Patent(s) and/or U.S. Patent Application Publication(s) on PTO/SB08 is/are not being submitted.
- ☐ B. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- ☐ C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

<<INSERT SERIAL NO. & FILING DATE>>

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

- ☐ 3. Cite No(s). _____ are not in the English language.
In accordance with 1.98(c), Applicant states:
- ☐ An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
- ☐ The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609).
- ☐ A concise explanation of the relevance of document(s) _____ is set forth as follows: [Insert concise explanation of relevance]
- ☐ A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.
- ☐ A concise explanation of document(s) _____ can be found on the attached sheet.

- ☒ 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).
- ☐ 5. Other information being provided for the examiner's consideration follows:

[A/An _____ Search Report, dated _____, which issued during the prosecution of _____ Application No. _____ which corresponds to the present application.]


6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: February 14, 2007

Respectfully submitted,

By  *Melvin C. Garner*
(53,970)

Melvin C. Garner

Registration No.: 26,272
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known Application Number 10/596,827-Conf. #1997 Filing Date June 26, 2006 First Named Inventor Naoyoshi Yamada Art Unit N/A Examiner Name Not Yet Assigned Attorney Docket Number 03702/0205073-USO	
Sheet	1	of	2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² -Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Round of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ¹
	CA	PATARROYO, Manuel, et al., "Leucocyte Adhesion to Cells in Immune and Inflammatory Responses," The Lancet, 2(8672), November 11, 1989, pp. 1139-1142.				
	CB	DUSTIN, Michael L., et al., "Role of Lymphocyte Adhesion Receptors in Transient Interactions and Cell Locomotion," Annual Review of Immunology, Vol. 9, 1991, pp. 27-56.				
	CC	SPRINGER, Timothy A., et al., "Adhesion Receptors of the Immune System," Nature, Vol. 346, August 2, 1990, pp. 425-434.				
	CD	DIAMOND, Michael S., et al., "ICAM-1 (CD54): A Counter-Receptor for Mac-1 (CD11b/CD18)," Journal of Cell Biology, Vol. 111, No. 6 (pt. 2), December 1990, pp. 3129-3139.				
	CE	ROSENSTEIN, Yvonne, et al., "CD43, A Molecule Defective in Wiskott-Aldrich Syndrome, Binds ICAM-1," Nature, Vol. 354, November 21, 1991, pp. 233-235.				
	CF	IIGO, Yutaka, et al., "ICAM-1-Dependent Pathway is Critically Involved in the Pathogenesis of Adjuvant Arthritis in Rats," The Journal of Immunology, Vol. 147, No. 12, December 15, 1991, pp. 4167-4171.				
	CG	KAVANAUGH, Arthur F., et al., "Treatment of Refractory Rheumatoid Arthritis with an Anti-CD54 (Intercellular Adhesion Molecule-1, ICAM-1) Monoclonal Antibody," Arthritis Rheum., 1992, Vol. 35 (supplement), No. 53.				
	CH	KAWASAKI, Katsutoshi, et al., "Antibodies Against Intercellular Adhesion Molecule-1 and Lymphocyte Function-Associated Antigen-1 Prevent Glomerular Injury in Rat Experimental Crescentic Glomerulonephritis," The Journal of Immunology, Vol. 150, No. 3, February 1, 1993, pp. 1074-1083.				
	CI	COSIMI, A. Benedict, et al., "In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts," The Journal of Immunology, Vol. 144, No. 12, June 15, 1990, pp. 4604-4612.				
	CJ	BARTON, Randall W., et al., "The Effect of Anti-Intercellular Adhesion Molecule-1 on Phorbol-Ester-Induced Rabbit Lung Inflammation," The Journal of Immunology, Vol. 143, No. 4, August 15, 1989, pp. 1278-1282.				

Examiner Signature	Date Considered
3105106 doc	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/596,827-Conf. #1997
				Filing Date	June 26, 2006
				First Named Inventor	Naoyoshi Yamada
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	03702/0205073-US0
Sheet	2	of	2		

	CK	SEKO, Yoshinori, et al., "Expression of Intercellular Adhesion Molecule-1 in Murine Hearts with Acute Myocarditis Caused by Coxsackievirus B3," J. Clin. Invest., Vol. 91, April 1993, pg. 1327-1336.	
	CL	WEGNER, Craig D., et al., "Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of Asthma," Science, Vol. 247, 1990, pg. 456-459.	
	CM	WALLACE, John L., et al., "Role of Endothelial Adhesion Molecules in NSAID-Induced Gastric Mucosal Injury," American Journal of Physiology, Vol. 265, 1993, pg. G833-898.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PTO/SG/08A/D